A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

NCT05192642 · clinicaltrials.gov ↗

COMPLETED

Status

368

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors Harboring NTRK Fusion

Interventions

DRUG: Larotrectinib(Vitrakvi, BAY2757556)
DRUG: Data on other treatments

Sponsor

Bayer